Clinical trials: Schistosomiasis Mansoni
Schistosoma Mansoni
Schistosoma Mansoni in Mwanza Region, Tanzania
The objective of this study is to determine the strategy for mass drug administration (MDA) which provides the greatest reductions in prevalence and intensity of Schistosoma mansoni in school-aged children after 4 years of…
- Trial name
- SCORE_PAR (NCT02162875)
- Testing
- Praziquantel
- Where
- Tanzania
- Volunteers
- 37,500 people
- Sponsor
- DBL -Institute for Health Research and Development
Schistosomiasis, Anemia
Schistosomiasis Effect on Response to Vaccines, Anaemia and Nutritional Status of Children of Northern Senegal
SchistoVAN aims to study the role of schistosomiasis infection in the modulation of the immune response of children to childhood vaccine antigens, as well as the impact of this infection on their nutritional status and their…
- Conditions
- Schistosomiasis, Anemia, Underweight, Stunting
- Trial name
- SchistoVAN (NCT01553552)
- Where
- Senegal
- Volunteers
- 99 people, healthy volunteers welcome
- Sponsor
- Biomedical Research Center EPLS
Schistosoma Mansoni
A Randomised Trial of Artesunate-sulfamethoxypyrazine/Pyrimethamine Versus Praziquantel for the Treatment of S. Mansoni
The purpose of this study is to determine the comparative efficacy of artesunate plus sulfamethoxypyrazine-pyrimethamine versus Praziquantel in the treatment of school children infected with S.mansoni in western Kenya.
- Trial name
- NCT01054651
- Testing
- Artesunate+Sulfamethoxypyrazine/pyrimethamine, Praziquantel
- Where
- Kenya
- Volunteers
- 212 people, healthy volunteers welcome
- Sponsor
- Kenya Medical Research Institute
Tuberculosis
Trial to Investigate the Effect of Schistosoma Mansoni Infection on the Response to Vaccination With MVA85A in BCG-vaccinated African Adolescents
Mycobacterium tuberculosis (M. tb) is a pathogen with worldwide distribution which infects humans causing tuberculosis (TB), a transmissible disease resulting in very high mortality and morbidity; development of an effective…
- Trial name
- TB036 (NCT02178748)
- Testing
- MVA85A
- Where
- Uganda
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Schistosomiasis
Effect of Concomitant Mansonella Perstans Microfilaremia on Immune Responses Following Single Dose Praziquantel in People With Schistosomiasis
Background: Schistosomiasis is a chronic infection. It is caused by parasitic worms called Schistosoma haematobium (Sh) that are spread by snails that live in rivers. It can lead to liver problems or bladder cancer.
- Trial name
- NCT02734186
- Testing
- Praziquantel
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Schistosoma Hematobium Infection, Schistosomiasis Mansoni
Safety and Efficacy of Mirazid for Schistosomiasis Treatment
Clinical Trial Phase:Phase III Primary Objectives: Compare Mirazid and Praziquantel cure rates for both Schistosoma species. Compare Mirazid and Praziquantel effect in lowering the intensity of infection for both Schistosoma…
- Trial name
- PHAR0211 (NCT01529710)
- Testing
- Myrrh
- Where
- 2 sites in Egypt
- Volunteers
- 200 people
- Sponsor
- Pharco Pharmaceuticals
Schistosomiasis Mansoni
Evaluation of Praziquantel Dosage for Treatment of Schistosomiasis in Brazil
The primary objective of this project is to evaluate the efficacy and safety of praziquantel 60 mg/kg in the treatment of schistosomiasis, as compared to the standard 40 mg/kg therapy in a representative community from a highly…
- Trial name
- NCT00403611
- Testing
- Praziquantel 60 mg/kg, Praziquantel 40 mg/kg
- Volunteers
- 196 people
- Sponsor
- Oswaldo Cruz Foundation
Schistosomiasis
Repeated Doses of Praziquantel in Schistosomiasis Treatment (RePST)
An open label, randomized controlled trial of single vs. multiple treatments of praziquantel in intestinal African schistosomiasis in Côte d'Ivoire This study aims to determine the efficacy of repeated (up to four times)…
- Trial name
- RePST (NCT02868385)
- Testing
- 4x Praziquantel, 1x Praziquantel
- Where
- Côte d’Ivoire
- Volunteers
- 167 people
- Sponsor
- Leiden University Medical Center
Schistosoma Mansoni
Clinical Evaluation of Ujiplus® Against Schistosoma Mansoni
Schistosomiasis is classified as among the world's neglected tropical diseases (NTD). Morbidity due to Schistosoma mansoni (S. mansoni) is greatest among school-age children who typically have the highest burden of infection.
- Trial name
- NCT04679831
- Testing
- Ujiplus®, Praziquantel 400mg
- Where
- Kenya
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Kenya Medical Research Institute
Intestinal Schistosomiasis
Schistosoma Mansoni Morbidity in Children Aged 1-5 Years
This study is about intestinal schistosomiasis, commonly known as bilharzia, in children aged 1-5 years along Lake Victoria shoreline.The children will be screened for S.
- Trial name
- NCT01901484
- Testing
- Praziquantel
- Where
- Uganda
- Volunteers
- 800 people, healthy volunteers welcome
- Sponsor
- Makerere University
Schistosomiasis, Malaria
The Effect of Praziquantel Treatment on Schistosoma Mansoni Morbidity and re-Infection Along Lake Victoria, Uganda
The overall objective of the project is to contribute to an increased knowledge about the effect of praziquantel on schistosomiasis related morbidity and re-infection level among communities living along Lake Victoria in Mayuge…
- Trial name
- NCT00215267
- Testing
- praziquantel
- Where
- Uganda
- Volunteers
- 540 people, healthy volunteers welcome
- Sponsor
- DBL -Institute for Health Research and Development
Soil Transmitted Helminths, Schistosomiasis Mansoni
Evaluation of an AI-DP for STH Deworming Programs: a Study Protocol
The goal of this observational study is to test a new AI diagnostic tool for detection, specification and quantification of parasitic infections (Ascaris, Trichuris, hookworm and S.
- Trial name
- KAKADU (NCT06055530)
- Testing
- Artificial Intelligence Digital Pathology
- Volunteers
- 1,100 people, healthy volunteers welcome
- Sponsor
- Enaiblers AB
Schistosoma Haematobium, Schistosoma Mansoni
Evaluation of Artesunate-mefloquine as a Novel Alternative Treatment for Schistosomiasis in African Children
The SchistoSAM study is an open label, two-arm, individually-randomized controlled trial with a non-inferiority design, conducted in northern Senegal.
- Trial name
- SchistoSAM (NCT03893097)
- Testing
- Praziquantel, Artesunate + Mefloquine
- Where
- Senegal
- Volunteers
- 726 people
- Sponsor
- Institute of Tropical Medicine, Belgium
Schistosomiasis
Anti-Schistosomiasis Vaccine: Sm14 Phase 2b-Sn in School Children
The clinical trial phase 2b is designed to assess the safety and the specific immune response of the active ingredient (protein + adjuvant) in healthy and then in infected school children from 8 to 11 years of age with intestinal…
- Trial name
- NCT03799510
- Testing
- Sm14, GLA-SE solution
- Where
- Senegal
- Volunteers
- 95 people, healthy volunteers welcome
- Sponsor
- Oswaldo Cruz Foundation
Schistosomiasis Mansoni, Circulating Cathodic Antigen Urine Based Dipstick
Evaluation of the Use of a Urin Test Strip to Determine the Spread of Schistosoma Infections in Areas Where Schistosomiasis Infections Are Low in Kenya
The purpose of this study is to evaluate the use of a urine test strip in diagnose schistosoma mansoni in areas of Kenya where the rate of infections are low.
- Trial name
- NCT00463307
- Where
- Kenya
- Volunteers
- 1,100 people
- Sponsor
- DBL -Institute for Health Research and Development
Schistosoma Mansoni
Filling Key Research Gaps With Clinical Implications in Mansonellosis and Schistosomiasis: a Network Approach
This is an experimental, multicenter, non-profit study promoted by the Department of Infectious and Tropical Diseases of the IRCCS (Istituto di Ricerca e Cura a carattere scientifico) Sacro Cuore Don Calabria of Negrar which aims…
- Trial name
- NCT06311344
- Testing
- Molecular biology analyses
- Where
- Italy
- Volunteers
- 200 people
- Sponsor
- IRCCS Sacro Cuore Don Calabria di Negrar
Schistosomiasis
An Open Label Dose Finding Safety and Efficacy in Children and Infants Infected With Schistosomiasis (S.Mansoni)
The Phase II study consisted of two parts, part 1 is open label, randomized, controlled and exploratory dose finding in children aged between 2 and 6 years infected with S. mansoni.
- Trial name
- NCT02806232
- Testing
- Biltricide (racemate praziquantel) oral tablets, Racemate Praziquantel ODT, Levo Praziquantel ODT
- Where
- Germany
- Volunteers
- 444 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Anemia, Intestinal Helminthiasis
A Study of Co-infections of HIV-1 and Schistosoma Mansoni and Its Impact on Praziquantel Treatment Outcomes
In this study, it is hypothesized that helminth infections modulate immune responses against HIV-1 infection resulting into increased HIV-1 multiplication, faster progression to AIDS and increased episodes of AIDS-related…
- Conditions
- Anemia, Intestinal Helminthiasis, Intestinal Schistosomiasis, Human Immunodeficiency Virus I Infection
- Trial name
- NCT01541631
- Testing
- Praziquantel and Albendazole
- Where
- 2 sites in Tanzania
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Catholic University of Health and Allied Sciences
Schistosomiasis Mansoni, Portal Hypertension
Treatment Schistosomal Portal Hypertension: Efficacy of Endoscopy or Surgery
Upper gastrointestinal bleeding (UGIB) is a major cause of morbidity and mortality in patients with portal hypertension secondary to schistosomiasis mansoni.
- Conditions
- Schistosomiasis Mansoni, Portal Hypertension, Upper Gastrointestinal Bleeding
- Trial name
- NCT01931826
- Testing
- Endoscopic treatment, Total EGDS+ endoscopy
- Where
- Brazil
- Volunteers
- 54 people
- Sponsor
- Universidade Estadual de Ciências da Saúde de Alagoas
Schistosomiasis
L-PZQ ODT in Schistosoma Infected Children
The study would evaluate the safety and efficacy of L-praziquantel orodispersible (L-PZQ ODT) tablets in Schistosoma infected children aged 3 months to 6 years.
- Trial name
- NCT03845140
- Testing
- L-PZQ ODT 50 mg/kg, Biltricide®, L-PZQ ODT 60 mg/kg
- Where
- 2 sites in Côte d’Ivoire, Kenya
- Volunteers
- 288 people
- Sponsor
- Merck KGaA, Darmstadt, Germany